Share-Based Payments (Tables)

9 Months Ended

Sep. 30, 2016

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2016			2015			2016			2015
Research and development	$	22.7		$	10.8		$	65.6		$	68.3
Selling, general and administrative	31.2			17.5			94.6			99.3
Restructuring charges	—			—			(1.8		)	—
Subtotal	53.9			28.3			158.4			167.6
Capitalized share-based compensation costs	(3.2		)	(2.8		)	(10.7		)	(8.4		)
Share-based compensation expense included in total cost and expenses	50.7			25.5			147.7			159.2
Income tax effect	(14.6		)	(6.4		)	(42.5		)	(46.0		)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	36.1		$	19.1		$	105.2		$	113.2

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2016			2015			2016			2015
Market stock units	$	5.7		$	7.3		$	27.0		$	33.4
Time-vested restricted stock units	28.5			30.4			92.5			94.1
Cash settled performance units	7.9			(9.5		)	12.7			17.5
Performance units	9.1			(2.8		)	17.3			11.6
Employee stock purchase plan	2.7			2.9			8.9			11.0
Subtotal	53.9			28.3			158.4			167.6
Capitalized share-based compensation costs	(3.2		)	(2.8		)	(10.7		)	(8.4		)
Share-based compensation expense included in total cost and expenses	$	50.7		$	25.5		$	147.7		$	159.2

The following table summarizes our equity grants to employees, officers and directors under our current stock plans:



	For the Nine Months Ended September 30,
	2016	2015
Market stock units	166,000	181,000
Cash settled performance shares	86,000	115,000
Performance units	67,000	89,000
Time-vested restricted stock units	603,000	393,000